Differential expression of Vegfr-2 and its soluble form in preeclampsia.

ABSTRACT:

Background

Several studies have suggested that the main features of preeclampsia (PE) are consequences of endothelial dysfunction related to excess circulating anti-angiogenic factors, most notably, soluble sVEGFR-1 (also known as sFlt-1) and soluble endoglin (sEng), as well as to decreased PlGF. Recently, soluble VEGF type 2 receptor (sVEGFR-2) has emerged as a crucial regulator of lymphangiogenesis. To date, however, there is a paucity of information on the changes of VEGFR-2 that occur during the clinical onset of PE. Therefore, the aim of our study was to characterize the plasma levels of VEGFR-2 in PE patients and to perform VEGFR-2 immunolocalization in placenta.

Methodology/principal findings

By ELISA, we observed that the VEGFR-2 plasma levels were reduced during PE

SUBMITTER: Munaut C 

PROVIDER: S-EPMC3299790 | biostudies-literature | 2012

REPOSITORIES: biostudies-literature